Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
McKinsey
Baxter
Mallinckrodt
Merck

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR NIMBEX


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Nimbex

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00912990 ↗ Pediatric Elective Intubation With and Without Muscle Relaxation Utilizing the Shikani Optical Stylet Terminated Rady Children's Hospital, San Diego N/A 2007-01-01 The investigators' primary specific aims are to demonstrate that: 1. Pediatric patients with normal airways, undergoing elective surgical procedures, can be successfully intubated when deeply sedated, without the use of muscle relaxants using the Shikani Optical Stylet. 2. Shikani intubation of pediatric patients is equally effective in children that are deeply sedated or paralyzed as evidenced by a non-significant difference in: - Time to intubation (defined as no more than a 30 second time difference between the two groups); - Incidence of adverse events.
NCT01573715 ↗ Effects of Neuromuscular Blocking Agents (NMBA) on the Alteration of Transpulmonary Pressures at the Early Phase of Acute Respiratory Distress Syndrome (ARDS) Unknown status Assistance Publique Hopitaux De Marseille Phase 4 2012-04-01 Mortality in Acute Respiratory Distress Syndrome is high (40 to 60 %). Protective mechanical ventilation, until 2010, was the cornerstone of the ARDS therapeutic strategies. Recently, a prospective multicenter study demonstrates that a 48h continuous infusion of neuromuscular blocking agents (NMBA) have a positive impact on mortality of ARDS patients. (Papazian et al. ACURASYS Study. NEJM 2010; 363:1107-16). The mechanisms through which NMBAs could improve survival remain speculative. They are as follows: - reduction of the consumption of oxygen linked to ventilatory workload; - increase of chest wall compliance improving mechanical ventilation during ARDS and better adaptation to the protective ventilation strategy; - anti-inflammatory effect contributing to a reduction in pulmonary inflammation and improvement in oxygenation, - reduction of the variations of transpulmonary pressure (TPP) by the way of better synchronisation between patient and the ventilator. The use of NMBA could also reduce the ventilator induced lung injury by a better control of TPP.
NCT01690338 ↗ A Study of Residual Curarization Incidence in China Unknown status Central South University Phase 4 2012-10-01 The purpose of this study is to determine the incidence of residual curarization in PACU and relevant risk factors.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nimbex

Condition Name

Condition Name for Nimbex
Intervention Trials
Neuromuscular Blockade 3
Acute Respiratory Distress Syndrome 2
Perioperative/Postoperative Complications 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Nimbex
Intervention Trials
Respiratory Distress Syndrome 3
Acute Lung Injury 3
Respiratory Distress Syndrome, Newborn 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Nimbex

Trials by Country

Trials by Country for Nimbex
Location Trials
United States 20
China 12
Czechia 1
Thailand 1
France 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Nimbex
Location Trials
California 2
New York 1
Colorado 1
Indiana 1
Louisiana 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Nimbex

Clinical Trial Phase

Clinical Trial Phase for Nimbex
Clinical Trial Phase Trials
Phase 4 5
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Nimbex
Clinical Trial Phase Trials
Completed 8
Unknown status 2
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Nimbex

Sponsor Name

Sponsor Name for Nimbex
Sponsor Trials
The First Affiliated Hospital of Guangzhou Medical University 1
University of Sao Paulo 1
Eastern Hepatobiliary Surgery Hospital 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Nimbex
Sponsor Trials
Other 35
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Colorcon
Baxter
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.